Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Contingent liabilities Contingent Liabilities [Member] Contingent Liabilities Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] InvIOs investment InvIOs [Member] InvIOs Percentage of milestones (as a percent) Milestone Compensation Rate Milestone Compensation Rate Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Reported Value Measurement Reported Value Measurement [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Settlement of XOMA deferred consideration Payment for contingent consideration liability, investing activities Payment for Contingent Consideration Liability, Investing Activities Compensation Employee-related Liabilities, Current Kinnate programs Kinnate programs [Member] Kinnate programs CCB Notes CCB Notes [Member] CCB Notes Development and Licensing of Biopharmaceutical Assets Development And Licensing of Biopharmaceutical Assets [Member] Development And Licensing of Biopharmaceutical Assets Derivative Instrument [Axis] Derivative Instrument [Axis] Securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt instrument, convertible, conversion price Debt Instrument, Convertible, Conversion Price Consolidated Entities [Axis] Consolidated Entities [Axis] Shares acquired, average cost per share Shares Acquired, Average Cost Per Share Tolerance Therapeutics (Tzield®) Tolerance Therapeutics (Tzield®) [Member] Tolerance Therapeutics (Tzield®) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Short-term portion of financial royalty assets, net Financial Royalty Assets, Current Financial Royalty Assets, Current Consolidated Entities [Domain] Consolidated Entities [Domain] Other Investments Other Investments Policy [Policy Text Block] Other Investments Policy Below 3 million Below Milestone [Member] Below Milestone XOMA Acquisition XOMA Acquisition [Member] XOMA Acquisition Unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accretion of short-term investments Accretion (Amortization) of Discounts and Premiums, Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Notes Receivable Notes Receivable [Member] Purchasers Purchasers [Member] Purchasers Kinnate Kinnate [Member] Kinnate Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Customer relationships Customer Relationships [Member] Royalty Method [Domain] Royalty Method [Domain] Royalty Method [Domain] Long-term portion of financial royalty assets, net Financial Royalty Assets, Non Current Financial Royalty Assets, Non Current Schedule of Derivative Assets Schedule of Derivative Assets at Fair Value [Table Text Block] Entity Address, City or Town Entity Address, City or Town Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan [Member] Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Statement of Financial Position [Abstract] Total definite lived intangible assets Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Settlement of receivable from RemainCo Proceeds from Equity Method Investment, Distribution, Return of Capital Kinnate CVR - Kinnate programs Kinnate CVR - Kinnate Programs [Member] Kinnate CVR - Kinnate Programs Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Milestone payable Milestone Payable Milestone Payable Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Metabasis CVR payments Metabasis CVR Payments [Member] Metabasis CVR payments Orchestra BioMed Orchestra BioMed [Member] Orchestra BioMed Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Shares available for future purchases (in shares) Share-Based Payment Arrangement, Shares Expected to be Repurchased, Next Fiscal Period Vidutolimod Vidutolimod [Member] Vidutolimod Convertible Senior Notes due 2031 - Initial Purchase Option Convertible Senior Notes due 2031 - Initial Purchase Option [Member] Convertible Senior Notes due 2031 - Initial Purchase Option Schedule of Reconciliation of Level 3 Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Proceeds from financial royalty assets Proceeds From Financial Royalty Assets Proceeds From Financial Royalty Assets Debt Conversion, Converted Instrument, Amount Above Principal Debt Conversion, Converted Instrument, Amount Above Principal Debt Conversion, Converted Instrument, Amount Above Principal Net proceeds from debt issuance Proceeds from Debt, Net of Issuance Costs Credit losses related to available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff Ownership percentage Equity Method Investment, Maximum Ownership Percentage Equity Method Investment, Maximum Ownership Percentage Document Period End Date Document Period End Date Preferred stock outstanding (in shares) Preferred Stock, Shares Outstanding Debt instrument, principal amount Debt Instrument, Face Amount Debt instrument term Debt Instrument, Term Pelthos Pelthos Technologies [Member] Pelthos Technologies Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Fair Value Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Fair value adjustments to contingent liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Current operating lease liabilities Operating Lease, Liability, Current Financial royalty assets, fair value disclosure Financial Royalty Assets, Fair Value Disclosure Financial Royalty Assets, Fair Value Disclosure Earnings per share Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Series A Warrants Series A Warrants [Member] Series A Warrants Qarziba QARZIBA [Member] QARZIBA Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Discount Rate Measurement Input, Discount Rate [Member] Summary of Goodwill and Other Identifiable Intangible Assets Intangible Asset, Including Goodwill, after Accumulated Amortization [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Business Acquisition, Commercial Products Business Acquisition, Commercial Products Business Acquisition, Commercial Products Product royalty rate Product Royalty Rate Product Royalty Rate Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Schedule of Components Of Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Income Tax Disclosure [Abstract] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Vabysmo Vabysmo [Member] Vabysmo Kinnate CVR - Exarafenib Exarafenib [Member] Exarafenib Credit Facility [Domain] Credit Facility [Domain] Warrants And Option Warrants And Option [Member] Warrants And Option Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net identifiable assets acquired Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Line of Credit Facility [Table] Line of Credit Facility [Table] Other expense items, net Other Expense Items, Net Other Expense Items, Net U.S. Treasuries US Treasury Securities [Member] Other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Share purchase price as percent of market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Fair Value Option, Other Eligible Items Fair Value Option, Other Eligible Items [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Noncurrent derivative assets Total noncurrent derivative assets Derivative Asset, Noncurrent Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Dilutive potential common shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Summary of Investment Holdings Summary of Investment Holdings [Line Items] 2030 Convertible Notes hedge and warrant transactions, net of tax (Note 7) Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Payout range (as a percent) Share-Based Compensation, Achievement Of Performance Criteria, Payout Range, Percent Share-Based Compensation, Achievement Of Performance Criteria, Payout Range, Percent Equity securities in Zerion Equity Securities In Zerion [Member] Equity Securities In Zerion Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Fair value of convertible senior notes outstanding (Level 2) Long-Term Debt, Fair Value Depreciation of property and equipment Depreciation Plan Name [Domain] Plan Name [Domain] Scenario [Domain] Scenario [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Balance at beginning of period (in USD per share) Balance at end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Operating Lease, Right-of-Use Asset Hurdle One Hurdle One [Member] Hurdle One Funding Allocation [Domain] Funding Allocation [Domain] Funding Allocation [Domain] Net assets acquired Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Royalties Royalties Royalty [Member] Interest in sales revenue (as a percent) Sales Contract, Interest In Sales Revenue Sales Contract, Interest In Sales Revenue Expiration Date Trading Arrangement Expiration Date Sales revenue milestone Sales Revenue Milestone Threshold Sales Revenue Milestone Threshold Excess net cash distribution Cash Acquired in Excess of Payments to Acquire Business REC-4881 REC-4881 [Member] REC-4881 Ordinary Shares Ordinary Shares [Member] Ordinary Shares Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Disposal Group, Including Discontinued Operations Disposal Group, Including Discontinued Operations [Line Items] Outstanding options that are exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Mezagitamab Mezagitamab [Member] Mezagitamab Proceeds from common stock issuance, net of commissions and fees Proceeds from Issuance of Common Stock Accounts receivable, net Business Combination, Recognized Asset Acquired, Receivable, Current Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Deferred Tax Asset, Valuation Allowance [Table] Deferred Tax Asset, Valuation Allowance [Table] LeonaBio LeonaBio [Member] LeonaBio Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Milestone [Axis] Milestone [Axis] Milestone Net income (loss) Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Debt Covenant Period [Domain] Debt Covenant Period [Domain] Debt Covenant Period [Domain] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Segments [Domain] Segments [Domain] Asset acquisition, consideration transferred, including capitalized transaction costs Asset Acquisition, Consideration Transferred, Including Capitalized Transaction Costs Asset Acquisition, Consideration Transferred, Including Capitalized Transaction Costs Debt Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Share repurchase in connection with the Notes (Note 9) Share Repurchase in Connection with ProceedsnFrom Debt Issuance Share Repurchase in Connection with ProceedsnFrom Debt Issuance Debt issuance costs, net Debt Issuance Costs, Net Business Combination [Table] Business Combination [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Total stockholders’ equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent Other assets Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent ASSETS Assets [Abstract] Contractual relationships Contractual Rights [Member] Other investments Total other investments Fair value on December 31, 2025 Fair value on September 30, 2026 Other Investments Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Ojemda Ojemda [Member] Ojemda Goodwill and intangible asset impairment Intangible Asset, Including Goodwill, Impairment Loss Current portion of convertible senior notes, net Senior Notes, Current Insider Trading Policies and Procedures [Line Items] Performance Shares Performance Shares [Member] Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Private Placement Private Placement [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table] Xepi Xepi [Member] Xepi Purchase of Convertible Senior Notes hedge Payments for Derivative Instrument, Financing Activities Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Proceeds from sale of short-term investments Proceeds from Sale of Short-Term Investments BioInvent BioInvent [Member] BioInvent Entity Central Index Key Entity Central Index Key Other Contingent liabilities - Other [Member] Contingent liabilities - Other Elutia (CorMatrix) Elutia (CorMatrix) [Member] Elutia (CorMatrix) XOMA Royalty Corporation XOMA Royalty Corporation [Member] XOMA Royalty Corporation Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Amended Credit Agreement Amended Credit Agreement [Member] Amended Credit Agreement Contingent liabilities Fair value of contingent earn-out payment Business Combination, Contingent Consideration, Liability, Fair Value Disclosure Business Combination, Contingent Consideration, Liability, Fair Value Disclosure Other Other [Member] Other Precombination services value Business Combination, Share Based Compensation, Precombination Services, Value Business Combination, Share Based Compensation, Precombination Services, Value Ownership [Axis] Ownership [Axis] Current contingent liabilities Current Portion Of Liability For Contingent Value Rights Current portion of liability for contingent value rights. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Investment, Name [Axis] Investment, Name [Axis] Equity-method investment Business Combination, Recognized Asset Acquired, Equity Method Investment Business Combination, Recognized Asset Acquired, Equity Method Investment Income from Pelthos Transaction Income From Divestiture Transactions [Member] Income From Divestiture Transactions Other Royalty Intangible, Other [Member] Royalty Intangible, Other Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Income Contract And Revenue Income, Other [Member] Contract And Revenue Income, Other Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Restricted Stock Awards Restricted Stock [Member] Accumulated other comprehensive income AOCI Attributable to Parent [Member] Asset acquisition, royalty rights Asset Acquisition, Royalty Rights Asset Acquisition, Royalty Rights 2031 Convertible Senior Notes 2031 Convertible Senior Notes [Member] 2031 Convertible Senior Notes All Individuals All Individuals [Member] Miplyffa Miplyffa [Member] Miplyffa Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period Asset acquisition, option to acquire incremental royalty rights, maximum, amount Asset Acquisition, Option To Acquire Incremental Royalty Rights, Maximum, Amount Asset Acquisition, Option To Acquire Incremental Royalty Rights, Maximum, Amount Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Option Volatility Measurement Input, Option Volatility [Member] Previously Reported Previously Reported [Member] Statement [Line Items] Statement [Line Items] Total assets Assets Convertible Debt Convertible Debt [Member] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Ficlatuzumab Ficlatuzumab [Member] Ficlatuzumab Schedule of Fair-Value Options Awarded to Employees and Directors Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Interest expense Interest expense Interest Expense, Nonoperating Loan receivable, conversion price Loan Receivable, Conversion Price Loan Receivable, Conversion Price Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Total liabilities assumed Business Combination, Recognized Liability Assumed, Liability PEO PEO [Member] Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Goodwill Goodwill Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Other Financial Royalty, Other [Member] Financial Royalty, Other Number of positions in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Accounts payable and accrued liabilities Business Combination, Recognized Liability Assumed, Accounts Payable, Current Retained earnings Retained Earnings [Member] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Financial Royalty Assets, net Financial Royalty Assets [Policy Text Block] Financial Royalty Assets Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate notes/bonds Corporate Debt Securities [Member] Diluted net (loss) income per share (in USD per share) Earnings Per Share, Diluted Unrealized (loss) gain on available-for-sale investments, net of tax Unrealized gain (loss) on equity method investments Unrealized Gain (Loss) on Investments Litigation Case [Domain] Litigation Case [Domain] Intangible Asset, Finite-Lived Intangible Asset, Finite-Lived [Line Items] Ownership [Domain] Ownership [Domain] Measurement Input, Share Price Measurement Input, Share Price [Member] Total identifiable assets acquired Business Combination, Recognized Asset Acquired, Asset Allowance Financial Royalty Assets, Allowance Financial Royalty Assets, Allowance Fair value Intangible Asset, Finite-Lived, Acquired Contingent Liability Type [Axis] Contingent Liability Type [Axis] Contingent Liability Type Financial royalty assets, effective interest rate method Effective Interest [Member] Effective Interest Total revenues and income Total revenues and income Revenue from Contract with Customer, Excluding Assessed Tax Additional principal amount Line of Credit Facility, Remaining Borrowing Capacity LAVA CVR LAVA CVR [Member] LAVA CVR Schedule of Equity Method Investments Equity Method Investments [Table Text Block] LAVA CVR payments LAVA CVR Payments [Member] LAVA CVR payments Arecor Limited Arecor Limited [Member] Arecor Limited Share repurchase in connection to the 2030 Notes Stock Repurchased During Period, Value Business Business Spin-Off And Migration [Policy Text Block] Business Spin-Off And Migration Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Purchases of short-term investments Payments to Acquire Short-Term Investments John Kozarich [Member] John Kozarich Cost of Captisol Cost, Direct Material After one year through five years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Andrew Reardon [Member] Andrew Reardon HilleVax HilleVax [Member] HilleVax Change in estimated fair value of contingent liabilities Gain (loss) in estimated fair value of contingent liabilities Non Cash Change In Estimated Fair Value Of Contingent Value Rights Sale of Stock [Axis] Sale of Stock [Axis] Accrued debt issuance costs Accrued Debt Issuance Costs Incurred But Not Yet Paid Accrued Debt Issuance Costs Incurred But Not Yet Paid Non-operating income and expenses: Other Nonoperating Income (Expense) [Abstract] Convertible Senior Notes due 2030 - Initial Purchase Option Convertible Senior Notes due 2030 - Initial Purchase Option [Member] Convertible Senior Notes due 2030 - Initial Purchase Option Ohtuvayre inventors Ohtuvayre Inventors [Member] Ohtuvayre Inventors Fair value adjustments to partner program derivatives Fair value adjustments to partner program derivatives Derivative, Gain (Loss) on Derivative, Net Operating (loss) income Net (loss) income Operating Income (Loss) Acquisition-related cost, expensed Business Combination, Separately Recognized Transaction, Acquisition-Related Cost, Expensed Volixibat Volixibat [Member] Volixibat Business Combination, Recognized Asset Acquired, Financial Royalty Asset Business Combination, Recognized Asset Acquired, Financial Royalty Asset Business Combination, Recognized Asset Acquired, Financial Royalty Asset XOMA Acquisition Business Combination [Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Corporate equity securities Equity Securities [Member] 2031 Notes Option 2031 Notes Option [Member] 2031 Notes Option Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Restricted Cash and Cash Equivalent Item [Line Items] Restricted Cash and Cash Equivalent Item [Line Items] Common stock issued (in shares) Common Stock, Shares, Issued Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Scenario, Adjustment Scenario, Adjustment [Member] Maximum loss exposure, amount, aggregate carrying amount of interests Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Aggregate Carrying Amount Of Interests Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Aggregate Carrying Amount Of Interests Royalty Method Royalty Method [Axis] Royalty Method Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Additional ordinary shares (in shares) Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Warrant related to the 2030 Notes Warrant Related To The 2030 Notes [Member] Warrant Related To The 2030 Notes Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Deferred income taxes, net Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Termination Date Trading Arrangement Termination Date Other Commitments [Axis] Other Commitments [Axis] At-the Market Equity Offering At-The Market Equity Offering [Member] At-The Market Equity Offering Subsequent Events [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cetrelimab Cetrelimab [Member] Cetrelimab Pelthos Transaction Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Pelthos Convertible Notes Pelthos Convertible Notes [Member] Pelthos Convertible Notes Other current liabilities Other Liabilities, Current Contract revenue and income Contract Revenue And Other Income [Member] Contract Revenue And Other Income Total current derivative assets Derivative Asset, Current Convertible receivable, receivable value Convertible Receivable, Receivable Value Convertible Receivable, Receivable Value Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Value-added tax Value Added Tax Receivable Net, Current Value Added Tax Receivable Net, Current Repayments of convertible debt Repayments of Convertible Debt Debt instrument, redemption price(as a percent) Debt Instrument, Redemption Price, Percentage Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Total operating costs and expenses Operating Costs and Expenses Arrangement Duration Trading Arrangement Duration Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Royalties owed to third parties Accrued Royalties Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Definite-lived intangible assets Intangible Asset, Finite-Lived, before Accumulated Amortization Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Consolidated leverage ratio Debt Instrument, Covenant Compliance, Consolidated Leverage Ratio, Maximum Debt Instrument, Covenant Compliance, Consolidated Leverage Ratio, Maximum Deferred tax assets Business Combination, Recognized Asset Acquired, Deferred Tax Asset Capvaxive Capvaxive [Member] Capvaxive Total Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Pelthos Conversion Option Pelthos Conversion Option [Member] Pelthos Conversion Option Operating costs and expenses: Operating Costs and Expenses [Abstract] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Trade name Trade Names [Member] Equity Award [Domain] Award Type [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Level 3 Fair Value, Inputs, Level 3 [Member] U.S. Government Agencies US Government Agencies Debt Securities [Member] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share Price Share Price Stock price trigger to classify convertible debt as current (as a percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Restricted cash Restricted Cash Above 3 million Above Milestone [Member] Above Milestone Shares issued, value Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value Legal Entity [Axis] Legal Entity [Axis] Interest expense Interest Expense, Debt Equity Method Investments Equity Method Investments [Policy Text Block] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Professional fees Accrued Professional Fees, Current Other Purchasers Other Purchasers [Member] Other Purchasers AvenCell AvenCell [Member] AvenCell Purchases of derivatives Payments for Derivative Instrument, Investing Activities Non-NEOs Non-NEOs [Member] Cash payments for acquisition Payments to Acquire Businesses, Gross Investment owned, net assets, percentage Equity Method Investment, Ownership Percentage Income from financial royalty assets Financial Royalty Assets [Member] Financial Royalty Assets Syndexis Syndexis [Member] Syndexis Accounts Receivable and Allowance for Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Schedule of Equity of the Convertible Senior Notes Schedule of Debt [Table Text Block] Investment, Name [Domain] Investment, Name [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of Accounting for Share-Based Compensation Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Customer deposit Contract with Customer, Liability, Current Repurchase of common stock Repurchase of common stock Payments for Repurchase of Common Stock Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Co-venturer Co-venturer [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Notes Payable, Current and Noncurrent [Abstract] Notes Payable, Current and Noncurrent [Abstract] US District Court for the Northern District of Ohio US District Court For The Northern District Of Ohio [Member] US District Court For The Northern District Of Ohio Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Maximum loss exposure, amount, additional committed equity funding Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Additional Committed Equity Funding Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Additional Committed Equity Funding Product and Service [Axis] Product and Service [Axis] Equity securities, FV-NI Pelthos Common Shares Equity Securities, FV-NI Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Noncurrent restricted cash Restricted Cash, Noncurrent Payments to acquire loan Payments to Acquire Loans Receivable Change in contingent consideration, liability decrease Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Anti-TL1A Anti-TL1A [Member] Anti-TL1A Investment Holdings [Table] Investment Holdings [Table] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Financial royalty assets, interest acquired, percentage Financial Royalty Assets, Interest Acquired, Percentage Financial Royalty Assets, Interest Acquired, Percentage Estimated fair value Debt Securities, Available-for-Sale Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate LeonaBio Warrants LeonaBio Warrants [Member] LeonaBio Warrants contractual interest expense Interest Expense, Debt, Excluding Amortization Derivative Contract [Domain] Derivative Contract [Domain] Pulmokine Pulmokine [Member] Pulmokine Total liabilities and stockholders’ equity Liabilities and Equity Total goodwill and other identifiable intangible assets, net Intangible Asset, Including Goodwill, after Accumulated Amortization Acquired equity method investment from XOMA Acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Stock Options Stock options Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party [Domain] Related and Nonrelated Parties [Domain] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Business Combination, Consideration Transferred, Equity Interest Business Combination, Consideration Transferred, Equity Interest [Table Text Block] Valuation Allowance [Line Items] Valuation Allowance [Line Items] Convertible Senior Notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Income taxes receivable Income Taxes Receivable, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Unrealized gain (loss) on hybrid instrument, net Unrealized Gain (Loss) on Hybrid Instrument, Net Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Basis of Presentation [Table] Basis of Presentation [Table] Basis of Presentation. 2031 Notes hedge and warrant transactions, net of tax Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt D-Fi D-Fi [Member] D-Fi After one year through five years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value CyDex CyDex [Member] CyDex Price per share Sale of Stock, Price Per Share Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Acquisition of royalty receivables Payments To Acquire Royalty Receivables Payments To Acquire Royalty Receivables Investor Group Investor Group [Member] Investor Group Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at September 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Adjustment to Compensation: Adjustment to Compensation [Axis] Payments to CVR holders and other contingent payments Payments To Contingent Value Right Holders Payments To Contingent Value Right Holders Business Combination, Intangible Asset, Acquired, Finite-Lived Business Combination, Intangible Asset, Acquired, Finite-Lived [Table Text Block] Annual revenue Royalty Income, Revenue Threshold Royalty Income, Revenue Threshold Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount April 2023 Repurchase Agreement April 2023 Repurchase Agreement [Member] April 2023 Repurchase Agreement Payments to acquire productive assets Payments to Acquire Productive Assets Ligand Ligand Pharmaceuticals Inc. [Member] Ligand Pharmaceuticals Inc. Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Number of contingent value rights outstanding Number Of Contingent Value Rights Outstanding Number Of Contingent Value Rights Outstanding Credit Facility [Axis] Credit Facility [Axis] Royalty Rights Royalty Rights [Member] Royalty Rights Total assets Assets, Fair Value Disclosure Contracted royalty revenue Finance Agreement, Contracted Royalty Revenue Finance Agreement, Contracted Royalty Revenue Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hurdle [Axis] Hurdle [Axis] Hurdle Debt Instrument [Line Items] Debt Instrument [Line Items] Additional paid in capital Additional Paid-in Capital [Member] (Gain) loss from short-term investments Gain (Loss) on Short-term Investments Gain (Loss) on Short-term Investments Acecor Warrants Acecor Warrants [Member] Acecor Warrants Agenus Warrant And Castle Creek Warrant Agenus Warrant And Castle Creek Warrant [Member] Agenus Warrant And Castle Creek Warrant Name Trading Arrangement, Individual Name Financial royalty asset Income Recognized Financial Royalty Asset Income Recognized Financial Royalty Asset Royalty income rate (as percent) Royalty Income Rate, Base Tier Royalty Income Rate, Base Tier Cash and cash equivalents Cash and Cash Equivalent Measurement Input, Expected Term Measurement Input, Expected Term [Member] Company Selected Measure Amount Company Selected Measure Amount Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block] Loss (gain) from change in fair value of equity-method investments and other investments Equity Securities, FV-NI, Unrealized Gain (Loss) Depreciation of fixed assets and amortization of intangible assets Depreciation, Depletion and Amortization Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Metabasis Metabasis [Member] Metabasis Non-PEO NEO Non-PEO NEO [Member] Convertible receivable, embedded conversion value Convertible Receivable, Embedded Conversion Value Convertible Receivable, Embedded Conversion Value Agenus Bot/Bal Agenus Bot/Bal [Member] Agenus Bot/Bal Dilutive potential common shares: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Award Timing Method Award Timing Method [Text Block] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other Obligation, Other [Member] Obligation, Other Operating Lease, Incremental Borrowing Rate Operating Lease, Incremental Borrowing Rate Operating Lease, Incremental Borrowing Rate Asset acquisition financial royalty assets Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Net (loss) income Net (loss) income Net income (loss) Net income Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Outstanding options that are exercisable, weighted average exercise price (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Number of civil complaints filed against entity Loss Contingency, New Claims Filed, Number Business Combination, Intangible Asset, Acquired, Indefinite-Lived Business Combination, Intangible Asset, Acquired, Indefinite-Lived [Table Text Block] Revenues and income: Revenues [Abstract] Change in fair value Fair Value, Option, Changes in Fair Value, Gain (Loss) Vabysmo Agenus Bot/Bal Agenus, Inc. [Member] Agenus, Inc. Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Qarziba Tolerance Therapeutics [Member] Tolerance Therapeutics Schedule of Goodwill and Other Identifiable Intangible Assets Intangible Asset and Goodwill [Table Text Block] Schedule of Other Assets Schedule of Other Assets, Noncurrent [Table Text Block] Asset Acquisition [Table] Asset Acquisition [Table] Statistical Measurement [Domain] Statistical Measurement [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Business combination, acquisition-related cost, expense Business Combination, Acquisition-Related Cost, Expense Share-based compensation expense Share-Based Payment Arrangement, Expense, after Tax Number of shares to be purchased under agreement (in shares) Securities Purchase Agreement, Number Of Shares Securities Purchase Agreement, Number Of Shares Restricted Stock Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Convertible Senior Notes due 2030 Convertible Senior Notes due 2030 [Member] Convertible Senior Notes due 2030 Common stock, $0.001 par value; 60,000 shares authorized; 20,001 and 19,774 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Castle Creek Warrants Castle Creek Warrants [Member] Castle Creek Warrants Performance period for awards (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Inventory write-down Inventory Write-down Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Settlement of related party debt Repayments of Related Party Debt Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Payments under finance lease obligations Finance Lease, Principal Payments Proceeds from Pelthos investors Proceeds from Investors, Financing Activities Proceeds from Investors, Financing Activities Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Kyprolis Kyprolis [Member] Kyprolis Schedule of Available-for-Sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Gain on Pelthos Transaction Gain (Loss) on Disposition of Other Assets Loss Contingencies [Table] Loss Contingencies [Table] Covenant minimum consolidated EBITDA Line Of Credit Facility, Covenant Minimum Consolidated EBITDA Line Of Credit Facility, Covenant Minimum Consolidated EBITDA Maximum loss exposure, amount, potential additional payment Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Potential Additional Payment Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount, Potential Additional Payment Deferred income taxes, net Increase (Decrease) in Deferred Income Taxes Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Payments to acquire equity securities, fv-ni Payments to Acquire Equity Securities, FV-NI Warrant related to the 2031 Notes Warrant Related To The 2031 Notes [Member] Warrant Related To The 2031 Notes Foreign currency translation adjustment, net of tax Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Non-Accural Method Non-Accural Method [Member] Non-Accural Method Assets: Assets, Fair Value Disclosure [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Kinnate CVR - exarafenib Kinnate CVR - exarafenib [Member] Kinnate CVR - exarafenib Shares used in basic per share calculation (in shares) Weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Loss Contingencies [Line Items] Loss Contingencies [Line Items] Receivable with imputed interest, face amount Receivable with Imputed Interest, Face Amount Cash outflow on Pelthos Transaction (Note 3) Cash Divested from Deconsolidation Revenue from intangible royalty assets Intangible Royalty Assets [Member] Intangible Royalty Assets Annual royalty payment Annual Royalty Fee Annual Royalty Fee Number of contingent value rights issued Number Of Contingent Value Rights Issued Number Of Contingent Value Rights Issued Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Contract revenue and income Contract Revenue And Income [Member] Contract Revenue And Income Equity Method Investments, Fair Value Disclosure Equity Method Investments, Fair Value Disclosure Accounts receivable, issuance cost Accounts Receivable, Issuance Cost Accounts Receivable, Issuance Cost Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] RSUs vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Short-term investments Business Combination, Recognized Asset Acquired, Investment Business Combination, Recognized Asset Acquired, Investment Receivable [Domain] Receivable [Domain] Less: accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Current portion of convertible senior notes payable Long-Term Debt, Current Maturities Milestone [Domain] Milestone [Domain] Milestone [Domain] Agenus PIPE Series A Warrant Agenus PIPE Series A Warrant [Member] Agenus PIPE Series A Warrant Basis of Presentation Basis of Presentation [Line Items] Basis of presentation. Accounting Standards Updates, Recently Adopted and Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Accrued fixed asset purchases Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Amortization of debt issuance costs Amortization of Debt Issuance Costs Investment Transactions Asset Acquisition [Text Block] Preferred Class A Preferred Class A [Member] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Research and Development Funding Expense Research and Development Expense, Policy [Policy Text Block] Intangible assets Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Schedule of Other Investment Summary Investment Holdings [Table Text Block] Long-term debt Convertible senior notes, net Long-Term Debt Exercise price (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Asset acquisition, warrant Asset Acquisition, Warrant Asset Acquisition, Warrant Arecor Warrant Arecor Warrant [Member] Arecor Warrant Changes in operating assets and liabilities, net of acquisitions: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Leaona Bio Series B Warrants Leaona Bio Series B Warrants [Member] Leaona Bio Series B Warrants Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Unrecognized tax benefits Unrecognized Tax Benefits Stockholders' Equity Equity [Text Block] Security Exchange Name Security Exchange Name Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Contingent Liability Type [Domain] Contingent Liability Type [Domain] Contingent Liability Type [Domain] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Business combination, recognized identifiable assets acquired and liabilities assumed, contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Investments Investments [Roll Forward] Investments Total liabilities Liabilities, Fair Value Disclosure Impairment of equity method investment Equity Method Investment, Other-than-Temporary Impairment Zerion Pharma Zerion Pharma [Member] Zerion Pharma AT220 AT220 [Member] AT220 Equity securities in Primrose Bio Primrose Bio Primrose Bio [Member] Primrose Bio Accrued interest Interest Payable, Current Segment Information Segment Reporting, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] AvenCell Series C-1 Preferred Stock AvenCell Series C-1 Preferred Stock [Member] AvenCell Series C-1 Preferred Stock Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Payments for asset acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Amortization of debt discount and issuance fees Amortization of Debt Issuance Costs and Discounts Supplemental schedule of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] (Gain) loss on derivative instruments Unrealized Gain (Loss) on Derivatives Purchases of other investments Payments to Acquire Other Investments Principal amount of the 2031 and 2030 Notes outstanding Long-Term Debt, Gross (AT220) Financial Royalty AT220 Program [Member] AT220 Program Other long-term liabilities Other Sundry Liabilities, Noncurrent Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Business Combination, Voting Equity Interest Acquired, Percentage Business Combination, Voting Equity Interest Acquired, Percentage Agenus Warrant Warrant [Member] Shares used in diluted per share calculation (in shares) Shares used to compute diluted income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Derivative Assets Derivatives, Policy [Policy Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] Schedule of Short-Term Investments Schedule Of Short-Term investments [Table Text Block] Schedule Of Short-Term investments Maximum loss exposure, amount Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Impairment loss of financial royalty assets Impairment Loss On Financial Royalty Assets Impairment Loss On Financial Royalty Assets Financial Royalty Assets, net Financial Royalty Assets [Text Block] Financial Royalty Assets Current restricted cash Restricted Cash, Current Twist programs Twist programs [Member] Twist programs Letters of credit outstanding Letters of Credit Outstanding, Amount Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Line Items] Severance Costs Severance Costs Contingent consideration, minimum amount Business Combination, Contingent Consideration, Range of Outcomes, Minimum, Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Contract revenue Contract Revenue [Member] Contract Revenue Total Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date Primrose Primrose mRNA [Member] Primrose mRNA Nonvested at beginning of period (in USD per share) Nonvested at end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Pelthos shares received in exchange for LNHC, Inc. business Noncash Portion Of Compensation for Sales of Business, Share Value Noncash Portion Of Compensation for Sales of Business, Share Value Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] (Decrease) increase of mark-to-market adjustment of CVR liability Liabilities, Fair Value Adjustment Asset Acquisition [Domain] Asset Acquisition [Domain] Tangible asset impairment charges Tangible Asset Impairment Charges Effective interest rate (percent) Receivable with Imputed Interest, Effective Yield (Interest Rate) Amended ESPP Amended ESPP [Member] Amended ESPP Acquired derivative assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Income tax receivable and payable Increase (Decrease) in Income Taxes Receivable Noncurrent portion of convertible senior notes, net Senior Notes, Noncurrent Share based compensation, services value Business Combination, Share Based Compensation, Services, Value Business Combination, Share Based Compensation, Services, Value AvenCell Series C-2 Warrant AvenCell Series C-2 Warrant [Member] AvenCell Series C-2 Warrant Schedule of Computation of Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] Minimum Minimum [Member] Asset acquisition, deferred consideration payable Asset Acquisition, Deferred Consideration Payable Asset Acquisition, Deferred Consideration Payable Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Investments, fair value Investments, Fair Value Disclosure Schedule of Revenue by Source Disaggregation of Revenue [Table Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Net carrying value Financial Royalty Assets, Net Financial Royalty Assets, Net Business Combination Business Combination [Line Items] Common stock authorized (in shares) Common Stock, Shares Authorized CECL adjustment to financial royalty assets Current And Expected Credit Loss Adjustment Current And Expected Credit Loss Adjustment Exercise Price Award Exercise Price Authorized stock repurchase amount Share Repurchase Program, Authorized, Amount Business Combination, Separately Recognized Transaction, Payment to Purchase Previously Held Shares Business Combination, Separately Recognized Transaction, Payment to Purchase Previously Held Shares Business Combination, Separately Recognized Transaction, Payment to Purchase Previously Held Shares Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Unamortized debt discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Rilvegostomig Rilvegostomig [Member] Rilvegostomig Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity method investments Fair value on December 31, 2025 Fair value on September 30, 2026 Equity Method Investments Payments to acquire common stock and warrants Payments to Acquire Common Stock and Warrants Payments to Acquire Common Stock and Warrants Equity Component [Domain] Equity Component [Domain] Fair value adjustments to derivative assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Measurement Input Type [Domain] Measurement Input Type [Domain] Complete technology Patented Technology [Member] Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Inventory Inventory, Policy [Policy Text Block] Ryjunea Ryjunea [Member] Ryjunea Counterparty Name [Domain] Counterparty Name [Domain] Total non-operating (expenses) income, net Nonoperating Income (Expense) Funded By Partner Royalty And Milestone Receipts Funded By Partner Royalty And Milestone Receipts [Member] Funded By Partner Royalty And Milestone Receipts Restricted stock and performance stock awards Restricted Stock And Performance Shares [Member] Restricted Stock And Performance Shares Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Balance at beginning of period (in shares) Balance at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Interest income Interest Income, Operating Hurdle [Domain] Hurdle [Domain] Hurdle [Domain] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subcontractor Accrued Subcontractor Expenses, Current Accrued Subcontractor Expenses, Current Repayments of Debt Repayments of Debt Business Combination [Domain] Business Combination [Domain] Commitment and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Zelsuvmi Zelsuvmi [Member] Zelsuvmi Weighted Average Weighted Average [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Combination [Axis] Business Combination [Axis] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to acquire notes receivable Payments to Acquire Notes Receivable LAVA LAVA [Member] LAVA Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Ersodetug Ersodetug [Member] Ersodetug Document Transition Report Document Transition Report Derivative assets Business Combination, Recognized Asset Acquired, Derivative Asset Current Business Combination, Recognized Asset Acquired, Derivative Asset Current (Loss) gain from short-term investments Gain (Loss) on Investments Deferred income taxes, net Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other Commitments [Domain] Other Commitments [Domain] City Area Code City Area Code Asset acquisition, consideration transferred, capitalized transaction costs Asset Acquisition, Consideration Transferred, Capitalized Transaction Costs Asset Acquisition, Consideration Transferred, Capitalized Transaction Costs 2030 Convertible Senior Notes Convertible Debt Securities [Member] Subsequent Events Subsequent Events [Text Block] Others Others [Member] Others Financial royalty assets: long term Business Combination, Recognized Asset Acquired, Financial Royalty Asset Non-current Business Combination, Recognized Asset Acquired, Financial Royalty Asset Non-current Other Other Other Name Forgone Recovery, Individual Name Funding Allocation [Axis] Funding Allocation [Axis] Funding Allocation Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Castle Creek Investment Castle Creek Investment [Member] Castle Creek Investment Sato Sato [Member] Sato AvenCell Purchase And Sale Agreement AvenCell Purchase And Sale Agreement [Member] AvenCell Purchase And Sale Agreement Entity [Domain] Entity [Domain] Consideration paid for an interest in potential development milestone Consideration Paid For An Interest In Potential Development Milestone Consideration Paid For An Interest In Potential Development Milestone Preferred stock issued (in shares) Preferred Stock, Shares Issued Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Business Acquisition, Development Programs Business Acquisition, Development Programs Business Acquisition, Development Programs Operating lease liabilities Business Combination, Recognized Liability Assumed, Lease Obligation Gross proceeds from issuance of Convertible Senior Notes Proceeds from Convertible Debt Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Share-based compensation Share-Based Payment Arrangement, Expense Measurement Basis [Axis] Measurement Basis [Axis] Product royalty (as a percent) Product Royalty Percentage Product Royalty Percentage Number of shares of common stock available (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Orchestra Warrant Orchestra Warrant [Member] Orchestra Warrant Fair value on December 31, 2025 Fair value on September 30, 2026 Investments Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Income taxes payable Taxes Payable, Current Ohtuvayre inventors Financial Ohtuvayre Inventors [Member] Financial Ohtuvayre Inventors Revision of Prior Period [Domain] Revision of Prior Period [Domain] Forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash and cash equivalents Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Postcombination services value Business Combination, Share Based Compensation, Postcombination Services, Value Business Combination, Share Based Compensation, Postcombination Services, Value Debt discount and payment of debt issuance cost Payments of Debt Issuance Costs Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Liabilities: Liabilities, Fair Value Disclosure [Abstract] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Schedule of Net Assets Acquired Business Combination [Table Text Block] Business Combination, Pro Forma Information Business Combination, Pro Forma Information [Table Text Block] Research and development Research and Development Expense Pelthos Pelthos [Member] Pelthos Adjustments to reconcile net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Asset acquisition, deferred consideration, number of installments Asset Acquisition, Deferred Consideration, Number Of Installments Asset Acquisition, Deferred Consideration, Number Of Installments Financial Instruments [Domain] Financial Instruments [Domain] Lease amortization expense Finance Lease And Operating Lease, Right-of-Use Asset, Amortization Finance Lease And Operating Lease, Right-of-Use Asset, Amortization Derivative asset Derivative Asset Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Increase (decrease) in allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Underlying Securities Award Underlying Securities Amount Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Schedule of Financial Royalty Assets Schedule of Financial Royalty Assets [Table Text Block] Schedule of Financial Royalty Assets Forfeited (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Operating lease right-of-use assets Business Combination, Recognized Asset Acquired, Right of Use Asset Business Combination, Recognized Asset Acquired, Right of Use Asset Preferred Stock Preferred Stock [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items] Inventory Increase (Decrease) in Inventories Amortization of intangibles Amortization of intangibles Cost, Amortization Business Combination, Acquiree's Revenue since Acquisition Date, Actual Business Combination, Acquiree's Revenue since Acquisition Date, Actual Short-term Investments Marketable Securities, Policy [Policy Text Block] Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Assets and Liabilities Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Investment amount, at closing Other Commitment, Investment Amount, Current Other Commitment, Investment Amount, Current Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Long-term contingent liabilities Liability For Contingent Value Rights Derivative [Line Items] Derivative [Line Items] Convertible Senior Notes due 2031 Convertible Senior Notes due 2031 [Member] Convertible Senior Notes due 2031 Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Osavampator Osavampator [Member] Osavampator Share repurchase in connection with the Notes (Note 9) (in shares) Stock repurchased during period (in shares) Stock Repurchased During Period, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Gross carrying value Financial Royalty Assets, Gross Financial Royalty Assets, Gross Within one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Oak Hill programs Oak Hill programs [Member] Oak Hill programs Schedule of Stock Option Plan Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measure: Measure [Axis] Amortization of debt discount (premium) Amortization of Debt Discount (Premium) AvenCell embedded derivative AvenCell Derivative Asset [Member] AvenCell Derivative Asset Equity Components [Axis] Equity Components [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Covenant Initial Period Debt Covenant Initial Period [Member] Debt Covenant Initial Period Entity Small Business Entity Small Business Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Useful Life (years) Intangible Asset, Finite-Lived, Acquired, Weighted-Average Amortization Period Property, Plant, and Equipment Property, Plant, and Equipment [Line Items] Financial royalty assets, measurement input (percent) Financial Royalty Asset, Measurement Input Financial Royalty Asset, Measurement Input MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Total other assets Other Assets, Noncurrent Document Type Document Type Cash paid for XOMA acquisition, net of cash and restricted cash received Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Royalty income rate, upper tier (as percent) Royalty Income Rate, Upper Tier Royalty Income Rate, Upper Tier Proceeds from sale of derivatives Proceeds from Derivative Instrument, Investing Activities Subsequent Event Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Business Acquisition, Additional Assets In Various Stages of Development Business Acquisition, Additional Assets In Various Stages of Development Business Acquisition, Additional Assets In Various Stages of Development Warrants term (in years) Warrants and Rights Outstanding, Term Commitments and contingencies Commitments and Contingencies Schedule of Other Long Term Liabilities Other Noncurrent Liabilities [Table Text Block] Captisol Material Sales, Captisol [Member] Material Sales, Captisol Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Warrant measurement input (as a percent) Warrants and Rights Outstanding, Measurement Input Teriparatide injection Teriparatide Injection [Member] Teriparatide Injection Program Related Obligations Program Related Obligations [Member] Program Related Obligations Executive Category: Executive Category [Axis] Receivable Type [Axis] Receivable Type [Axis] Schedule of Restricted Stock Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Debt Covenant Subsequent Period Debt Covenant Subsequent Period [Member] Debt Covenant Subsequent Period Pelthos Series A convertible preferred shares Pelthos Common Shares And Series A convertible Preferred Shares [Member] Pelthos Common Shares And Series A convertible Preferred Shares Counterparty Name [Axis] Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost [Abstract] LeonaBio Warrants LeonaBio Series A Warrant [Member] LeonaBio Series A Warrant Phage display library Phage display library [Member] Phage display library Metabasis Therapeutics Metabasis Therapeutics [Member] Metabasis Therapeutics [Member] Inventory Inventory Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount PeliCRM197 PeliCRM197 [Member] PeliCRM197 Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Recognized research and development expense Payments To Acquire Financial Royalty Assets And Recognized Research And Development Expense Payments To Acquire Financial Royalty Assets And Recognized Research And Development Expense PEO Name PEO Name Payments for purchase of equity Payments for Repurchase of Equity Taxes paid Income Tax Paid, before Refund Received Cash withheld Cash Acquired from Acquisition Other Segment Reporting, Other Segment Item, Amount Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Measurement input Business Combination, Contingent Consideration, Liability, Measurement Input RemainCo RemainCo [Member] RemainCo Ixinity Ixinity [Member] Ixinity Other commitment, investment amount, maximum Other Commitment, Investment Amount, Maximum Other Commitment, Investment Amount, Maximum Employee Stock Purchase Plan Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] (AT229) Financial Royalty AT292 Program [Member] AT292 Program Intnagible Asset Fair Value Measurement input Intnagible Asset Fair Value Measurement input Intnagible Asset Fair Value Measurement input Options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenue and Income Revenue [Policy Text Block] Other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from maturity of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Acquired contingent liabilities from XOMA Acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements) Basic net (loss) income per share (in USD per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Total current assets Assets, Current Former XOMA Royalty Stockholders Former XOMA Royalty Stockholders [Member] Former XOMA Royalty Stockholders Payments to CVR holders Payments to Contingent Value Right Holders, Financing Activity Payments to Contingent Value Right Holders, Financing Activity Insider Trading Arrangements [Line Items] Noncurrent portion of convertible senior notes payable Long-Term Debt, Excluding Current Maturities Pelthos shares received for a bridge loan cancellation Noncash or Part Noncash Acquisition, Bridge Loan Extinguished By Stock Issuance Noncash or Part Noncash Acquisition, Bridge Loan Extinguished By Stock Issuance Vaxneuvance Vaxneuvance [Member] Vaxneuvance Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Convertible Note Hedge and Warrant Convertible Note Hedge and Warrant [Member] Convertible Note Hedge and Warrant Unrealized (loss) gain on available-for-sale securities, net of tax Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Ohtuvayre Intangible Ohtuvayre [Member] Intangible Ohtuvayre Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Obligations, Fair Value Disclosure Obligations, Fair Value Disclosure Fair Value Measurement [Domain] Fair Value Measurement [Domain] APEIRON APEIRON [Member] APEIRON Contingent earn-out payment Contingent liability Business Combination, Contingent Consideration, Liability Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Agenus PIPE Series B Warrant Agenus PIPE Series B Warrant [Member] Agenus PIPE Series B Warrant Other investments, location Investment, Type [Extensible Enumeration] Equity Awards Adjustments Equity Awards Adjustments [Member] Asset Acquisition Asset Acquisition [Line Items] Settlement of receivable from RemainCo against vendor invoices Noncash Or Part Noncash, Settlement Of Equity Method Investment Receivable Noncash Or Part Noncash, Settlement Of Equity Method Investment Receivable Qarziba Qarziba [Member] Qarziba Research and Development Funding Research and Development Funding [Member] Research and Development Funding HilleVaxCVR HilleVaxCVR [Member] HilleVaxCVR Initial Purchaser Warrants Initial Purchaser Warrants [Member] Initial Purchaser Warrants Plan Name [Axis] Plan Name [Axis] Derivative liability, measurement input Derivative Liability, Measurement Input Boston Lease payments Boston Lease Payments [Member] Boston Lease payments Sale of stock, authorized offering amount Sale Of Stock, Authorized Offering Amount Sale Of Stock, Authorized Offering Amount Other non-operating income (expense), net Other Nonoperating Income (Expense) Short-Term Investments Short-Term Investments [Member] Equity issuance cost Equity Issuance Cost Equity Issuance Cost Acquire investments Payments to Acquire Investments Restricted cash Business Combination, Recognized Asset Acquired, Restricted Cash Business Combination, Recognized Asset Acquired, Restricted Cash Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative General and Administrative Expense Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Pelthos loan receivable Pelthos Loan Receivable [Member] Pelthos Loan Receivable Share Repurchase Program [Axis] Share Repurchase Program [Axis] Class of Stock [Domain] Class of Stock [Domain] Statement of Cash Flows [Abstract] Payments for repurchase of warrants Payments for Repurchase of Warrants Rylaze Rylaze [Member] Rylaze Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Asset acquisition, embedded derivative Asset Acquisition, Embedded Derivative Asset Acquisition, Embedded Derivative Filspari Filspari [Member] Filspari Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Income Tax Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Acquisition of financial royalty assets Acquisition of financial royalty assets Payments To Acquire Financial Royalty Assets Payments To Acquire Financial Royalty Assets Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Aggregate acquisition amount Business Combination, Consideration Transferred Entity Filer Category Entity Filer Category Short-term investments Short-Term Investments Non-cash income from financial royalty assets Non-cash Income From Financial Royalty Assets Non-cash Income From Financial Royalty Assets (Loss) gain from change in fair value of equity-method investments and other investments Gain (Loss) From Change In Fair Value Of Equity-Method Investments and Other Investments Gain (Loss) From Change In Fair Value Of Equity-Method Investments and Other Investments Contingent liabilities Business Combination, Recognized Liability Assumed, Contingent Liability Revision of Prior Period [Axis] Revision of Prior Period [Axis] Within one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Payables Rate To Holders Payables Rate To Holders Payables Rate To Holders Other segment items: Segment Reporting, Reconciliation of Other Item by Segment to Consolidated [Abstract] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Business combination common stock (in USD per share) Business Combination, Price Per Share Current assets: Assets, Current [Abstract] Derivative liabilities Derivative Liability Interest in potential development milestone (as a percent) Interest In Potential Development Milestone Interest In Potential Development Milestone Revenues and income Business Combination, Pro Forma Information, Pro Forma Revenue Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Entity Address, Address Line One Entity Address, Address Line One Boston Lease security deposit Boston Lease Security Deposit [Member] Boston Lease Security Deposit Addition of right-of-use assets and lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability RSUs vested (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Income tax benefit (expense) Income Tax Expense (Benefit) Convertible Notes Convertible Notes Payable [Member] Contingent consideration maximum, amount Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Deferred tax liability Deferred tax liability Business Combination, Recognized Liability Assumed, Deferred Tax Liability Financial royalty assets: short term Business Combination, Recognized Asset Acquired, Financial Royalty Asset Current Business Combination, Recognized Asset Acquired, Financial Royalty Asset Current Statement [Table] Statement [Table] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Net proceeds from stock option exercises and ESPP Proceeds from Stock Options Exercised Interest income Investment Income, Interest Receivable due from RemainCo Business Combination, Recognized Asset Acquired, Receivable, Current Other Business Combination, Recognized Asset Acquired, Receivable, Current Other Accrued Liabilities Accrued Liabilities [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block]